The global biomarker discovery outsourcing service market size was valued at USD 17.92 billion in 2025 and is projected to grow from USD 21.45 billion in 2026 to USD 90.40 billion by 2034, registering a CAGR of 19.70% during the forecast period (2026-2034). North America dominated the biomarker discovery outsourcing service market with a share of 43.21% in 2025.
The biomarker discovery outsourcing service market includes specialized research services provided by external laboratories and contract research organizations (CROs) to identify and validate biological indicators associated with diseases, treatment responses, and disease progression. Biomarker discovery outsourcing services are commonly classified under HSN Code 9981 (research and development services, where applicable) and SIC Code 8731 (Commercial Physical and Biological Research).
The biomarker discovery outsourcing service market demand is driven by investment in drug development, the need to identify disease-specific biological indicators, and interest in personalized medicine. Pharmaceutical and biotechnology companies are outsourcing proteomic biomarker discovery and genomic profiling services to access specialized analytical expertise, contributing to biomarker discovery outsourcing service market growth.
Download a Free Sample To learn more about this report,
Shift toward Multiomics-Based Biomarker Identification
The biomarker discovery outsourcing services market analysis shows a shift toward multiomics-based biomarker identification, which combines data from genomics, proteomics, metabolomics, and other biological disciplines. This approach helps researchers examine disease mechanisms from multiple biological perspectives and identify biomarkers that may be overlooked through single omics analysis.
Integration of Genomics, Proteomics, and Metabolomics in Biomarker Discovery
Integration of genomics, proteomics, and metabolomics is shaping the biomarker discovery outsourcing services market by enabling researchers to connect genetic variations with protein activity and metabolic changes. Outsourcing providers combine advanced analytical platforms and bioinformatics tools to process these complex datasets and identify potential disease indicators or treatment response markers.
Supply chain disruptions are expected to have a moderate impact on the biomarker discovery outsourcing service market share due to dependence on laboratory reagents, assay kits, analytical instruments, and biological samples. The market is expected to follow a K-shaped recovery, as well-equipped contract research organizations can maintain operations. The market is expected to grow at a CAGR of 19.70%, but supply chain constraints could lower this by 1.5 percentage points, resulting in a growth of around 18.20%. As supply conditions normalize, the biomarker discovery outsourcing service market growth is expected to gradually return to 19.70%.
The biomarker discovery outsourcing service market forecasts strategic investment activity driven by AI-powered biomarker identification, advanced proteomics platforms, and improved analysis of tissue and protein level data.
Key Investment and Funding Activities in Biomarker Discovery Outsourcing Service Market, 2026
ViewsML
USD 4.9 million
In April 2026, ViewsML raised an oversubscribed seed funding round led by Wittington Ventures to commercialize its AI-powered virtual biomarker staining platform.
Resolute Bio
Approximately USD 11.6 million
In June 2026, Resolute Bio announced a seed round to develop its spatial proteomics platform for analyzing protein activity and tissue biology.
Adoption of Precision Medicine and Demand for Early Disease Detection Drive Market
Preference for personalized healthcare increases the need for biomarkers that help identify disease characteristics, predict treatment responses, and guide therapy selection. Pharmaceutical and biotechnology companies outsource biomarker discovery to access specialized analytical technologies and expertise.
Need to identify diseases at earlier stages is increasing research into biomarkers that can detect biological changes before symptoms become severe. Outsourcing biomarker discovery enables researchers to use advanced testing methods to identify and validate potential disease indicators, supporting the development of earlier diagnostic approaches and expanding demand for specialized discovery services.
Dependence on Specialized Laboratory Infrastructure and Limited Availability of Skilled Scientific Professionals Restrain Market Expansion
Biomarker discovery outsourcing services rely on advanced laboratory infrastructure, including high-throughput screening systems, mass spectrometry, sequencing platforms, and specialized analytical instruments. Establishing and maintaining these facilities requires substantial investment in equipment, calibration, and quality control.Biomarker discovery requires professionals with expertise in molecular biology, bioinformatics, genomics, proteomics, and data analysis. A shortage of experienced scientists can slow research workflows, affect data interpretation, and create challenges in validating potential biomarkers.
Expansion of Biomarker Discovery for Companion Diagnostics and Drug Development Offers Growth Opportunities
Biomarker discovery service providers can target pharmaceutical companies and diagnostic developers creating companion tests for targeted therapies. These services help identify biological markers that can guide treatment selection and assess patient responses to specific medicines. Revenue opportunities arise through biomarker profiling, assay development, validation services, and partnerships with pharmaceutical companies, contributing to biomarker discovery outsourcing service market growth.
Contract research organizations and specialized laboratory providers can target drug developers seeking biomarkers for patient selection, safety assessment, and evaluation of treatment effectiveness. Outsourced biomarker testing can help pharmaceutical companies access specialized technologies and scientific expertise without expanding internal laboratory capacity.
Predictive biomarkers accounted for the largest share of 38.5% due to its role in identifying patients likely to respond to specific treatments. Pharmaceutical and biotechnology companies use predictive biomarker analysis to support treatment selection and the development of personalized therapies.
Prognostic biomarkers are likely to witness a CAGR of 19.2% during the forecast period, driven by the need to assess disease progression and estimate clinical outcomes.
Request Customizationto receive a tailored report.
In 2025, oncology held the leading position with a 43.6% share, supported by the use of biomarkers in cancer diagnosis, patient stratification, and targeted therapy development.
Neurology is projected to undergo growth at a CAGR of 20.5% during the forecast period, driven by the need for biomarkers that support research into neurological disorders and disease progression. Biomarker discovery services can help identify measurable indicators for conditions such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
Biomarker identification accounted for a dominant share of 32.4% due to its importance in identifying and validating potential biological indicators during early-stage research. Outsourcing providers offer specialized analytical platforms and expertise to help researchers examine biological samples and identify candidate biomarkers.
Biomarker panel development segment is anticipated to record a growth rate of 22.3% during the forecast period, supported by interest in combining multiple biomarkers to improve disease characterization and patient assessment.
Pharmaceutical companies represented a leading share at 49.2%, reflecting their use of outsourced biomarker discovery to support drug development, clinical trials, and patient stratification. External service providers offer specialized technologies and scientific expertise that help pharmaceutical companies conduct biomarker research without building all capabilities internally.
Biotechnology companies will expand to 21.8% CAGR during the forecast period, fueled by the development of biologics, targeted therapies, and precision medicine approaches.
Speak to an Analystto discuss market opportunities.
The North America biomarker discovery outsourcing service market accounted for a dominant share of 43.21% in 2025.
U.S. National Cancer Institute’s Cancer Moonshot initiatives support biomarker-driven cancer research, including the identification and validation of molecular markers that can improve cancer detection and treatment selection. These programs rely on advanced biomarker analysis, molecular profiling, and validation methods to evaluate potential clinical applications.
Canada’s Genomics Research and Development Initiative (GRDI) supports federal research programs that apply genomics and advanced analytical methods to complex biological questions. These activities require reliable biomarker analysis and validation to establish the relevance of molecular findings, creating opportunities for specialized service providers supporting translational research and biomarker-based drug development.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific biomarker discovery outsourcing service market is anticipated to record a growth rate of 21.04% during the forecast period, making it the fastest-growing region.
India’s Genome India Project completed whole genome sequencing for more than 10,000 individuals representing the country’s diverse population groups. The resulting genomic dataset supports research into genetic variation and disease-associated markers, increasing the importance of specialized genomics, biomarker analysis, and bioinformatics capabilities for pharmaceutical and biotechnology research.
BioBank Japan is expanding its multi-omics research infrastructure using biological samples and clinical information from patients with various diseases. Its resources include genomic data, proteomic profiles, and metabolomic measurements, supporting biomarker discovery and the development of diagnostic and therapeutic approaches. The complexity of integrating these datasets creates a need for specialized analytical services and bioinformatics expertise.
Peking University’s Center for Precision Medicine Multi-omics Research integrates genomics, proteomics, metabolomics, and bioinformatics to identify and validate biomarkers for disease classification, diagnosis, and treatment assessment. This multidisciplinary approach highlights the need for advanced analytical platforms and computational expertise, supporting demand for outsourced biomarker discovery and validation services.
Europe's biomarker discovery outsourcing service market is estimated to register a growth rate of 18.2% during the forecast period.
Genomics England supports precision medicine through genomic analysis and research into the genetic factors associated with disease. Its work helps identify molecular markers that can guide treatment selection and diagnostic development, creating demand for specialized biomarker discovery, validation, and analytical services to support personalized medicine programs.
Federal Institute for Drugs and Medical Devices (BfArM) in Germany has conducted regulatory research into companion diagnostics, including methods for assessing the reliability of diagnostic tests used to select patients for targeted treatments. This work highlights the importance of biomarker validation and molecular analysis in precision medicine, supporting the need for specialized services that help pharmaceutical and diagnostic developers establish the clinical relevance of biomarkers.
Latin American biomarker discovery outsourcing service market is expected to experience a growth rate of 19.5% during the forecast period. Brazil’s Lead Optimization Latin America (LOLA) consortium supports collaborative drug discovery by connecting researchers and institutions working to identify and optimise potential drug candidates. Its work includes research into diseases such as Chagas disease, where identifying relevant biological targets.
Mexico’s participation in clinical research creates opportunities for biomarker analysis in drug development studies. Biomarker clinical phase outsourcing services help researchers assess biological responses, identify potential indicators of treatment effectiveness, and validate endpoints during clinical trials.
The Middle East & Africa biomarker discovery outsourcing service market is expected to achieve a growth rate of 17.6% during the forecast period. The University of Sharjah’s Human Disease Biomarkers Discovery Research Group uses proteomics, metabolomics, and computational analysis to identify and validate biomarkers associated with conditions such as cancer, diabetes, and infectious diseases.
South Africa’s African Clinical Multiome Atlas Platform (Clin-MAP), led by the Council for Scientific and Industrial Research (CSIR), is developing an integrated clinical dataset combining genomic, transcriptomic, microbiome, and proteomic information. The platform aims to improve understanding of disease biology in African populations and advance precision medicine.
The biomarker discovery outsourcing service market competitive landscape is highly fragmented, with established contract research organizations and specialized biomarker analysis companies. Key players such as Charles River Laboratories International, Evotec SE, WuXi AppTec, BioAgilytix Labs, and Discovery Life Sciences are estimated to account for 25–30% of the global biomarker discovery outsourcing service market share.
Established players compete mainly through analytical capabilities, assay development, and multiomics technologies. Emerging and regional players in the biomarker discovery outsourcing service market ecosystem focus on specialized biomarker platforms and application-specific solutions.
September 2026: Sciomics partnered with FluoSphera to launch a translational profiling service combining human relevant 3D multi tissue models with high content proteomic analysis.
September 2026: Proteome Sciences secured a significant clinical contract for its good clinical laboratory practice (GCLP) chemoproteomics platform
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
In Vitro Diagnostics Market Size, Share, Analysis, Report, 2034
Apoptosis Testing Market Size, Forecast, Demand, Opportunities, 2034
Cell Culture Media Bags Market Size, Forecast, Demand, 2034
Sample Preparation Market Size, Forecast, Opportunities, 2034
Cell Harvesting Systems Market Size, Forecast, Demand, Opportunities, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com